‘Velcade’ provides new hope to Mantle Cell Lymphoma patients!

Recent approval to the cancer drug ‘Velcade’ by FDA has provided new hope to patients suffering from Mantle Cell Lymphoma, an aggressive form of Non-Hodgkin’s Lymphoma. Mantle Cell Lymphoma is a disease, which cannot be cured with standard chemotherapy and Velcade is the first drug to receive FDA’s approval for the treatment of this disease. Watch this video to know more about this drug.